# Pfizer (incl. Seagen)

Source: https://nuclide.cc/companies/pfizer/  
Nuclide record `pfizer` (Company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Bought Seagen for $43B to become an ADC leader; also makes Ibrance, Lorbrena, Braftovi, and the first PROTAC.

## Summary

Pfizer, based in New York and listed as PFE, bought Seagen for 43 billion dollars to become an antibody-drug conjugate leader, and it also makes Ibrance, Lorbrena and Braftovi and developed the first PROTAC, vepdegestrant, with Arvinas. The ADC portfolio covers Padcev, Adcetris, Tivdak, Tukysa, disitamab vedotin outside China and sigvotatug vedotin; the small-molecule side includes palbociclib, atirmociclib, lorlatinib, encorafenib and talazoparib; and a PD-1 by VEGF bispecific was licensed from 3SBio in 2025 with 1.25 billion dollars upfront. Nuclide links it to the EV-302, CROWN, BREAKWATER, ECHELON-1 and INO-VATE papers, to ponsegromab and cachexia as a treatable disease, to LIV-1 as a target and to Pfizer Ventures. Whether Seagen's platform yields new ADCs rather than only sustaining the acquired ones is the open question. Each product has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Also known as: Seagen; Seagen (Pfizer); Seattle Genetics
- HQ: New York, NY
- Type: pharma
- Website: https://www.pfizer.com
- Ticker: PFE

## Sources

- Official website: https://www.pfizer.com

## Connected records

- drugs: [Dexrazoxane](https://nuclide.cc/drugs/dexrazoxane/), [Enzalutamide](https://nuclide.cc/drugs/enzalutamide/), [Sunitinib](https://nuclide.cc/drugs/sunitinib/)
- indications: [HER2-positive breast cancer](https://nuclide.cc/indications/breast-her2-positive/), [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/), [Pheochromocytoma and paraganglioma (PPGL)](https://nuclide.cc/indications/pheochromocytoma-paraganglioma/), [Prostate cancer](https://nuclide.cc/indications/prostate/), [Renal cell carcinoma](https://nuclide.cc/indications/rcc/)
- trials: [PROSPER](https://nuclide.cc/trials/prosper/)

---
JSON: https://nuclide.cc/api/v1/entities/pfizer.json